Veterinary Medicines

Advantage 250 mg Lösung zum Auftropfen für Hunde (≥ 10 - < 25 kg)

Authorised
  • Imidacloprid
Download as PDF

Product identification

Medicine name:
Advantage 250 mg Lösung zum Auftropfen für Hunde (≥ 10 - < 25 kg)
Advantage Vet. til hunde (10-25 kg) 100 mg/ml kutanopløsning
Active substance:
  • Imidacloprid
Target species:
  • Dog
Route of administration:
  • Cutaneous use

Product details

Active substance and strength:
  • Imidacloprid
    250.00
    milligram(s)
    /
    2.50
    millilitre(s)
Pharmaceutical form:
  • Cutaneous solution
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QP53AX17
Legal status of supply:
  • Veterinary medicinal product not subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Denmark
Available in:
  • Denmark
Package description:
  • Pack sizes 2.5 ml solution per pipette, Pack containing 1 unit dose pipettes, Container: White polypropylene pipettes with caps
  • Pack sizes 2.5 ml solution per pipette, Pack containing 2 unit dose pipettes, Container: White polypropylene pipettes with caps
  • Pack sizes 2.5 ml solution per pipette, Pack containing 3 unit dose pipettes, Container: White polypropylene pipettes with caps
  • Pack sizes 2.5 ml solution per pipette, Pack containing 4 unit dose pipettes, Container: White polypropylene pipettes with caps
  • Pack sizes 2.5 ml solution per pipette, Pack containing 6 unit dose pipettes, Container: White polypropylene pipettes with caps

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Informed consent application (Article 13c of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Elanco Animal Health GmbH
Marketing authorisation date:
Manufacturing sites for batch release:
  • KVP Pharma + Veterinaer Produkte GmbH
Responsible authority:
  • Danish Medicines Agency
Authorisation number:
  • 38495
Date of authorisation status change:
Reference member state:
  • Austria
Procedure number:
  • AT/V/0020/003
Concerned member states:
  • Denmark
  • Germany
  • Ireland
  • Italy
  • Netherlands
  • Norway
  • Spain
  • Sweden
  • United Kingdom (Northern Ireland)